News

Smart4fabry / News (Page 3)

Smart4Fabry & Rare diseases day 2018

Smart4Fabry project has been widely communicated during the last Rare Diseases Day (20/02/2018). Several actions have been taken, from contact with patients (Dr. Ibane Abasolo, Vall d Hebron Hospital) to press releases at national level. This effort has had impact in several mass media, with estimated audiences up to 1.500.000 people. Targeted audinces range from general public to clinicians and patients. You can find some of these impacts in the following links:

https://herenciageneticayenfermedad.blogspot.com/2018/02/investigadores-del-ciber-bbn-trabajan.html

http://biotech-spain.com/es/articles/smart4fabry-estudian-un-nuevo-tratamiento-para-la-enfermedad-de-fabry-gracias-a-la-nanomedicina/

http://www.periodistadigital.com/salud/medicina/2018/02/28/sabes-que-utilizan-la-nanomedicina-para-mejorar-el-abordaje-de-la-enfermedad-de-fabry.shtml

http://biotech-spain.com/es/articles/smart4fabry-estudian-un-nuevo-tratamiento-para-la-enfermedad-de-fabry-gracias-a-la-nanomedicina/

http://elmedicointeractivo.com/investigadores-del-ciber-bbn-trabajan-en-un-nuevo-tratamiento-para-la-enfermedad-de-fabry/

http://agencias.abc.es/agencias/noticia.asp?noticia=2751858

https://www.consalud.es/pacientes/dias-mundiales/estudian-un-nuevo-tratamiento-para-la-enfermedad-de-fabry-gracias-a-la-nanomedicina_47643_102.html

http://ecodiario.eleconomista.es/salud/noticias/8970479/02/18/Investigadores-espanoles-usan-la-nanomedicina-para-mejorar-el-tratamiento-de-la-enfermedad-de-

http://ecodiario.eleconomista.es/sociedad/noticias/8970466/02/18/Investigan-un-nuevo-tratamiento-para-la-enfermedad-de-fabry-basado-en-la-nanomedicina.html

http://www.infosalus.com/farmacia/noticia-utilizan-nanomedicina-mejorar-abordaje-enfermedad-fabry-20180228104334.html

http://www.teinteresa.es/espana/INVESTIGAN-TRATAMIENTO-ENFERMEDAD-BASADO-NANOMEDICINA_0_1969603250.html

https://www.consalud.es/pacientes/dias-mundiales/estudian-un-nuevo-tratamiento-para-la-enfermedad-de-fabry-gracias-a-la-nanomedicina_47643_102.html

http://noticiasdelaciencia.com/not/27657/estudian-un-nuevo-tratamiento-para-la-enfermedad-de-fabry-gracias-a-la-nanomedicina/

http://www.dicyt.com/noticias/estudian-un-nuevo-tratamiento-para-la-enfermedad-de-fabry-gracias-a-la-nanomedicina

https://www.catalunyavanguardista.com/nanomedicina-la-enfermedad-fabry/

SMART4FABRY III General Assembly

III General Assembly of Smart4Fabry project was held at Biopraxis Premises in Bilbao (Spain) from February 8th to 9th. All the Work Packages s have been reviewed, and critical steps for the future work have been defined.

Additionally, a web based managing tool has been also introduced, in order to allow a smooth coordinaton between partners and Work Packages. We took a picture of the consortium with our faces painted, to participate in the #ShowYourRare initiative for the Rare Disease Day 2018 (February 28th)

ETPN 2017

Our project coordinator, Dr. Nora Ventosa, presented the Smart4Fabry project at ETPN 2017. ETPN2017 has been the unique place to discover, to meet, to network, to prepare new projects, to brainstorm about Nanomedicine and its industrial expansion,  all in a cool and friendly atmosphere.

Among the key presentations on schedule this year, we shared the latests insights from the Nanomedicine Translation Hub, initiated by ETPN like the Translation Advisory Board, EUNCL, the Pilot Lines and many other key actions dedicated to all Nanomedicine and MedTech stakeholders.

The most relevant H2020 projects relatd to nanomedicine were also highlighted during a dedicated session, including Smart4Fabry

Smart4Fabry project presented at the 2nd Summer School of European & International Societies for Nanomedicine

2nd Summer School of European & International Societies for Nanomedicine was held in September in Barcelona and joined together all relevant stakeholders in nanomedicine, including scientists, technologists, companies, and clinicians. During the second day, several Smart4Fabry partners presented its relevant activities in Smart4Fabry.

Jaume Veciana, from CIBER-ICMAB-CSIC presented the overall technology, Ibane Abasolo from Vall d’ Hebron Research Institute (VHIR) explained the required preclinical design and Angel del Pozo from Biopraxis showed the challenges in GMP upscale.

Smart4Fabry Project presented at ICONAN 2017

ICONAN 2017 (International Conference On Nanomedicine And Nanobiotechnology) is an annual event that hosts high-profile plenary speakers, world-class researchers, oral and poster presentations, workshops, sponsor exhibits and afterworks.

Our colleague Solene Passemard, from ICMAB-CSIC, presented Smart4Fabry project to a selected audience of scientist and technologists on September 2017

A morning on Nanomedicine

Following the II General Meeting, the first Samrt4Fabry Workshop was held in the facilities of Technion, Haifa (Israel). This workshop covered different interesting Topics regarding Theragnostics, nature mimicking and nano targeted drug delivery .

Presentations were made by world class level scientists as Prof. Barenholz, Prof Schroeder, Prof. Peer, Prof Ventosa and Prof Machluf.

II General Meeting

General Meeting of the Smart-4-Fabry Project was held in the facilities of Technion, Haifa (Israel), from the 3th to the 5th July 2017. This meeting has been crucial to define the pathway to be followed by the project partners for the next months, with important achievements in terms of decisions to face the main project challenges.

Next meeting will be held in Miñano (Álava) in February

Smart4Fabry partners

Smart4Fabry partners (CIBER- BBN, BIONANONET and BIOPRAXIS) presented during the CLINAM 2017 summit from the 7 to the 10th May of 2017 their results, with two posters and a small-speech.

Assistència per part dels grups CIBER-BBN, Bionanonet I Biopraxis al congress CLINAM.
   

Everything is nano

Wenn Sie das Gefühl haben, dass unsere Welt immer kleiner wird, liegen Sie gar nicht so falsch. Nanotechnik wird in immer mehr Bereichen unseres Lebens eingesetzt. Das Forschungsteam der BioNanoNet GmbH sorgt dabei für Sicherheit.

Das Wort „Nano“ kommt aus dem Griechischen und ist eine grobe Übertreibung. Es bedeutet nämlich Zwerg. Doch die Teilchen, mit denen Nanotechnologien sich beschäftigen, sind noch wesentlich kleiner. Nur um eine grobe Vorstellung zu bekommen: Ein Nanometer ist ein millionstel Millimeter. Und alles, was größer als 100 Nanometer (also 0,0001 Millimeter) ist, ist schon zu groß für die Nanotechnologien. In diesen Dimensionen arbeiten die heimischen Unternehmen und Forschungsinstitute, die sich im Netzwerk BioNanoNet zusammengeschlossen haben, an innovativen Anwendungen. Unterstützt werden die Entwickler vom NanoSicherheits-Team der BioNanoNet GmbH. Geschäftsführer Andreas Falk präzisiert: „Die Identifikation möglicher Aufnahmewege, die Bewertung des potenziellen Risikos und die fallspezifische Strategie zur Maximierung der Sicherheit von Nanomaterialien gehören zu unseren Kernkompetenzen.“

Tinte aus winzigsten Teilen

Deshalb gibt es eine Reihe internationaler Projekte, in denen BioNanoNet verantwortlich für die Sicherheitsforschung ist. Zum Beispiel das Projekt „Hi-Response“: Nanotinten erlauben extrem hohe Auflösungen und Druckgeschwindigkeiten und eröffnen völlig neue Möglichkeiten im Druckbereich. Was aber im menschlichen Körper passiert, wenn beim Druckvorgang oder beim Kontakt mit nanogedrucktem Material diese winzig kleinen Teilchen eingeatmet, geschluckt oder über die Haut aufgenommen werden, ist noch nicht klar. Das festzustellen, ist der Job von BioNanoNet.

3-D-Druck im Nanobereich

Nanotechnologien ermöglichen auch winzige 3-D-Drucke, die in der Hochtechnologie eingesetzt werden. Zum Beispiel beim Bau von flexiblen Handy-Displays. Aber was passiert, wenn wir über das Display wischen, sich Nanoteilchen lösen, auf unseren Fingern haften bleiben, wir danach unser Essen angreifen und so die Teilchen aufnehmen? Oder Kleinkinder so ein Handy in die Hand bekommen und es in den Mund nehmen? Im Projekt „INSPIRED“ arbeitet die BioNanoNet daran mit, dass Nanoteilchen so eingebaut werden, dass diese zwar ihre Funktion behalten, aber sicher nicht in den menschlichen Körper gelangen.

Effizientere Medikamente

Nanoteilchen können aber auch ganz bewusst in unseren Körper gebracht werden. Im Projekt „Smart-4-Fabry“, an dem BioNanoNet ebenfalls mitwirkt, übernehmen spezielle Nanoteilchen den Transport von Wirkstoffen zielgerecht dorthin, wo sie im Körper gebraucht werden. Damit würde die Arznei wesentlich effizienter eingesetzt, deren vorzeitiger Abbau verhindert und der Organismus entlastet. Das wäre ein riesiger Schritt für die Medizin und die Patientensicherheit.

impuls/

VHIR participates in a European project against Fabry disease

The Drug Delivery and Targeting group from the CIBBIM-Nanomedicine at VHIR, led by Dr. Simó Schwartz Jr., participates in a new European project, which aims the innovation and improvement in the treatment for Fabry disease, a rare condition X-linked which affects 1 in 7.000 people approximately. The project is awarded with 5,8 milion in the Horizon 2020 program of the European Comission, and involves the participation of 14 institutions from academia and industry.

Fabry disease belongs to the lisosomal disorders group and it is characterized by the deficiency of the enzymatic activity of α-galactosidase A. The lack of this enzyme causes cell damage which affects the skin, the kidneys, the heart and the central nervous system, among others. Nowadays, the treatment for Fabry disease consists in the administration of the protein which the patients of Fabry disease do not have.

So as to improve the treatment against this rare disease, the VHIR investigators performed several previous studies which have led them to participate in this European Project. Specifically, they participate in the NanoFabry project, awarded by La Marató de TV3, the Lipocell project and Terarmet, a project awarded by the Ministerio de Economía y Competitividad. Dr. Ibane Abasolo, principal investigator of the SMART-4-FABRY in the CIBBIM group, explains that “with this project we will work in the possibility of crossing the blood-brain barrier, something that is crucial for the treatment of the lisosomal diseases and that could benefit other rare conditions with neurological affectation”.

Moreover, the advisory board of the SMART-4-FABRY involves the participation of Dr. Jordi Pérez, physician of the minor diseases unit of the Hospital Vall d’Hebron and Dr. Mari Carmen Domínguez, member of the CIBBIM-Nanomedicina VHIR group.

Dr. Abasolo assures that thanks to the participation of the VHIR and the rest of groups in this European project, “we will be ready to start the development of an innovative treatment, more beneficial for the patients”.

cibbim/